Status: Not yet recruiting
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
This study evaluates the diagnostic performance and safety of 68Ga-NYM032 PET/CT imaging in patients with suspected recurrence of prostate cancer.
Participants needed: 232
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: Norroy Bioscience Co., LTDUpdated: Jun 16, 2026
Eligibility criteria
Patient is male and aged >18 years old. [+5]
Participants who have previously participated in other interventional clinical t... [+4]